comparemela.com

Latest Breaking News On - End third level - Page 1 : comparemela.com

China s NMPA accepts Legend Biotech s NDA for cilta-cel - Pharmaceutical Business review

Cilta-cel is a BCMA-directed and genetically modified autologous T-cell immunotherapy that involves reprogramming a patient’s own T-cells with a transgene encoding a chimeric antigen receptor (CAR), which detects

Vistagen agrees to acquire Pherin Pharmaceuticals

Vistagen has signed a definitive agreement for the acquisition of clinical-stage drug development firm Pherin Pharmaceuticals.

FDA grants fast track designation for Kintara s breast cancer therapy

The US FDA has granted fast track designation (FTD) for Kintara Therapeutics’ REM-001, to treat cutaneous metastatic breast cancer (CMBC).

Everest regulatory updates in Taiwan, South Korea for Nefecon

The regulatory authorities in Taiwan and South Korea have granted fast-tracked approval process for Everest Medicines’ Nefecon.

SRI, Amylyx Pharmaceuticals partner to identify ALS drug candidates

SRI and Amylyx have joined forces to develop new drug candidates to treat amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.